EPISODE · Dec 19, 2023 · 1H 13M
NervGen's Clinical Trial (Episode 92)
from U2FP CureCast · host Matthew Rodreick & Jason Stoffer
Today’s conversation is a highly anticipated one. For years we’ve been hearing about the groundbreaking work of Jerry Silver to render the injury scar permeable to axon growth. That work led to development of the pharmacologic NVG-291 and the associated company NervGen Pharma. The research has finally advanced to a human SCI clinical trial, led by Monica Perez, PT, PhD, who's today's guest. Dr. Perez is the scientific chair of the Arm and Hands Lab at Shirley Ryan AbilityLab and a Professor of Physical Medicine and Rehabilitation at Northwestern University in Chicago. In this conversation we talk about what led Monica into SCI research, her role as Principal Investigator in this clinical trial, the background and study design of the trial and its current recruitment of participants. More info: https://u2fp.org/get-educated/curecast/episode-92.html
What this episode covers
Today’s conversation is a highly anticipated one. For years we’ve been hearing about the groundbreaking work of Jerry Silver to render the injury scar permeable to axon growth. That work led to development of the pharmacologic NVG-291 and the associated company NervGen Pharma. The research has finally advanced to a human SCI clinical trial, led by Monica Perez, PT, PhD, who's today's guest. Dr. Perez is the scientific chair of the Arm and Hands Lab at Shirley Ryan AbilityLab and a Professor of Physical Medicine and Rehabilitation at Northwestern University in Chicago. In this conversation we talk about what led Monica into SCI research, her role as Principal Investigator in this clinical trial, the background and study design of the trial and its current recruitment of participants. More info: https://u2fp.org/get-educated/curecast/episode-92.html
NOW PLAYING
NervGen's Clinical Trial (Episode 92)
No transcript for this episode yet
Similar Episodes
Jan 22, 2021 ·3m
Jan 20, 2021 ·30m
Jan 11, 2021 ·18m
Jan 10, 2021 ·0m
Mar 2, 2019 ·1m